Key result
Endothelin-1 infusion during coronary occlusion yielded greater endocardial blood flow than placebo (42 vs 14 ml/min/100 g, p=0.003) but decreased ischemic zone function during reperfusion (p<0.05).
Why the study?
Does endothelin-1 infusion alter coronary perfusion and mechanical function in normal and postischemic myocardium in a canine model?
Population
30 conscious chronically instrumented dogs
Comparison
Endothelin-1 infusion before, during, and after… vs Placebo infusion before, during, and after a…
Design
Preclinical
Follow-up
Acute (during and after 10-min coronary artery occlusion)
Authors
Loading...
Caution advised with ET-1 elevation in ischemia; leaves open translation from canine models to human trials.
Does endothelin-1 infusion alter coronary perfusion and mechanical function in normal and postischemic myocardium in a canine model?
Absolute Event Rate: 42% vs 14%
p-value: p=0.003
In a canine model of ischemia-reperfusion, pathophysiologic levels of endothelin-1 increased residual myocardial blood flow during coronary occlusion but paradoxically worsened mechanical function during reperfusion.
Donckier et al. (1994) studied Myocardial ischemia (n=30). Endothelin-1 (ET-1) vs. Placebo was evaluated on Endocardial blood flow in ischemic regions during coronary artery occlusion (p=0.003). Endothelin-1 infusion during coronary occlusion yielded greater endocardial blood flow than placebo (42 vs 14 ml/min/100 g, p=0.003) but decreased ischemic zone function during reperfusion (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: